Immorta Bio Inc., a leader in longevity-focused biotechnologies, announced today that it will present its latest developments at the upcoming Biotech Showcase in San Francisco, CA. The company’s presentation will provide insights into its groundbreaking research and technological advancements aimed at Treating Diseases of Aging and Treating Aging as Disease™. Details of the presentation are as follows: Event: Biotech Showcase 2025 Date: January 14, 2025 Time: 4 PM Pacific Location: Franciscan C, Ballroom Level

Diakonos Oncology, a clinical-stage biotechnology company leveraging proprietary dendritic cell technology to address critical and unmet therapeutic needs in late-stage and aggressive cancers, announced that it will present its latest developments at the Biotech Showcase in San Francisco, CA from January 13-15, 2025. Biotech Showcase is a premier event for private and micro-mid-cap biotechnology companies to highlight their innovation and connect with global investors and engage with executives from prominent biopharmaceutical interests. Diakonos Oncology will be represented by President and Chief Operating Officer Jay Hartenbach, who will be presenting on recent corporate milestones and research developments, including lead product DOC1021, a unique autologous dendritic cell vaccine (DCV), which will begin enrolling patients in its Phase 2 clinical trial for glioblastoma (GBM) in H1 2025 at leading treatment centers across the US. Details of the presentation are as follows: Event: Biotech… 

Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced European CE mark approval of the Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter for the treatment of cardiac arrhythmias. The Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter is an irrigated, contact-force sensing catheter powered by the TRUPULSE™ Generator, and is fully integrated with the CARTO™ 3 System for electro-anatomical mapping and for tag indexing.1 The company expects TRUPULSE™ Generator hardware compatibility in the first half of 2025. When fully approved, the platform will provide electrophysiologists with the ability to switch between radiofrequency (RF) and pulsed field (PF) energy in the same catheter they know and trust. The Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter is not currently approved in the United States. The Dual Energy THERMOCOOL SMARTTOUCH™ SF Catheter is designed on the same platform as the radiofrequency THERMOCOOL SMARTTOUCH™… 

MimiVax, Inc. and UI Pharmaceuticals have announced the successful clinical manufacture of SurVaxM, a novel immunotherapeutic vaccine targeting Glioblastoma (GBM), at UIP’s recently qualified $26M sterile manufacturing facility. This collaboration combines MimiVax’s innovative research with UIP’s expertise in formulation development and sterile production, accelerating the path to potentially transformative therapies for patients. About SurVaxM SurVaxM is a groundbreaking immunotherapeutic targeting survivin, a cell-survival protein prevalent in glioblastomas and many other cancers. This innovative immunotherapy is engineered to stimulate a patient’s immune system to recognize survivin-expressing cancer cells as foreign, thereby controlling tumor growth and recurrence. Currently, SurVaxM is being evaluated in a randomized Phase 2b clinical trial for glioblastoma at 11 leading cancer centers across the United States. Additional clinical trials are exploring its potential in multiple myeloma, neuro-endocrine tumors (NET), and pediatric relapsed high-grade glioma. MimiVax’s Glioblastoma treatment using… 

Regor announced its 12-week single-dose Phase 2a trial results for RGT-075, a once-daily oral GLP-1RA, reporting 5% placebo-adjusted weight-loss with no plateau.No treatment-related severe adverse events (AEs), with only 4% discontinuation rate due to AEs, same as placebo.Enrollment opening for its COMO-1 Phase 2b dose-finding study to read out Q4 2025

Schimpansen verfügen über genetische Anpassungen, die ihnen helfen, in unterschiedlichen Wald- und Savannenlebensräumen zu überleben. Dies ist das Ergebnis einer heute im Fachjournal „Science“ veröffentlichten Studie. Ein internationales Forschungsteam unter Federführung des University College London (UCL) zeigt, dass einige dieser Anpassungen die Tiere auch vor Malaria schützen könnten. Die Forschenden betonen, dass ihre Ergebnisse Einblicke… Schimpansen: Genetische Anpassungen schützen vor Malaria

Auf dem Pic du Midi in den Pyrenäen haben ETH-Forschende Feinstaub, Wolken und Regenwasser auf Spuren von Arsen untersucht. Und mit neu entwickelten Messmethoden haben sie die Transportwege des Umweltgifts in der Atmosphäre aufgeklärt. Arsen ist ein Spurenelement, das im Periodensystem gleich unter dem – für alle Lebewesen essenziellen – Phosphor liegt. Diese enge chemische… Arsenspuren im Regen deuten

Biofidelity, a leader in innovative genomic solutions, and CellCarta, the global contract research organization (CRO) partner of choice for biopharmaceutical companies seeking precision medicine solutions, today announced a strategic partnership agreement to utilize Biofidelity’s Aspyre® Lung in global clinical trials. Aspyre Lung simplifies the detection of established non-small cell lung cancer (NSCLC) biomarkers by analyzing both DNA and RNA from tissue and blood using a streamlined four-step workflow. Designed to run on existing qPCR platforms, it integrates seamlessly into laboratories globally and aligns with CellCarta’s mission to support global clinical trials through innovative genomic services. Under the terms of the strategic partnership agreement, CellCarta will set up and validate Aspyre Lung in their European laboratories first, followed by its US-based laboratories and will have non-exclusive rights to utilize Aspyre Lung for clinical trials globally. The partnership provides customers with revolutionary…